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Abstract
Background: Several studies have implicated a role of inflammation in the pathogenesis of lung damage in idiopathic
pulmonary fibrosis (IPF). Parenchymal lung damage leads to defects in mechanics and gas exchange and clinically manifests
with exertional dyspnea. Investigations of inflammatory cells in IPF have shown that eosinophils, neutrophils and CD8+
TLs may be associated with worse prognosis. We wished to investigate by quantitative immunohistochemistry infiltrating
macrophages, neutrophils and T lymphocytes (TLs) subpopulations (CD3+, CD4+ and CD8+) in lung tissue of patients with
IPF and their correlation with lung function indices and grade of dyspnoea.
Methods: Surgical biopsies of 12 patients with IPF were immunohistochemically stained with mouse monoclonal
antibodies (anti-CD68 for macrophages, anti-elastase for neutrophils, and anti-CD3, anti-CD4, anti-CD8 for CD3+TLs,
CD4+TLs, and CD8+TLs respectively). The number of positively stained cells was determined by observer-interactive
computerized image analysis (SAMBA microscopic image processor). Cell numbers were expressed in percentage of
immunopositive nuclear surface in relation to the total nuclear surface of infiltrative cells within the tissue (labeling Index).
Correlations were performed between cell numbers and physiological indices [FEV1, FVC, TLC, DLCO, PaO2, PaCO2
and P(A-a)O2)] as well as dyspnoea scores assessed by the Medical Research Council (MRC) scale.
Results: Elastase positive cells accounted for the 7.04% ± 1.1 of total cells, CD68+ cells for the 16.6% ± 2, CD3+ TLs for
the 28.8% ± 7, CD4+ TLs for the 14.5 ± 4 and CD8+ TLs for the 13.8 ± 4. CD8+TLs correlated inversely with FVC %
predicted (rs = -0.67, p = 0.01), TLC % predicted (rs = -0.68, p = 0.01), DLCO % predicted (rs = -0.61, p = 0.04), and
PaO2 (rs = -0.60, p = 0.04). Positive correlations were found between CD8+TLs and P(A-a)O2 (rs = 0.65, p = 0.02) and
CD8+TLs and MRC score (rs = 0.63, p = 0.02). Additionally, CD68+ cells presented negative correlations with both FVC
% predicted (rs = -0.80, p = 0.002) and FEV1 % predicted (rs = -0.68, p = 0.01).
Conclusion: In UIP/IPF tissue infiltrating mononuclear cells and especially CD8+ TLs are associated with the grade of
dyspnoea and functional parameters of disease severity implicating that they might play a role in its pathogenesis.
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Background
In usual interstitial pneumonia (UIP)/idiopathic pulmo-
nary fibrosis (IPF) the role of inflammation in the patho-
genesis of fibrosis is debatable [1-3]. Traditionally, UIP/
IPF was regarded to develop in response to chronic
inflammation of the lung parenchyma [4]. This view was
advanced from previous studies implicating a role of the
inflammatory cells including neutrophils, macrophages,
eosinophils and T lymphocytes (TLs), based on the obser-
vation of their accumulation in sites of disease activity [5-
8] or on their presence in high numbers in bronchoalveo-
lar lavage [9-12].
Actually, the current pathogenetic theory that holds in
UIP/IPF, implicates that fibrosis per se might progress
despite a paucity of interstitial inflammation [13]. How-
ever, even in this case, recent data still indicate the conten-
tion that the type of the inflammatory response may
modulate tissue injury, fibrosis or both [3,4]. Animal
studies imply that TLs might play a role in the initiation
and the evolution of pulmonary fibrosis. They also sug-
gest that different TLs subpopulations, including both
CD4+ and CD8+ subsets, might contribute through their
ability to secrete fibrogenic cytokines [14,15]. Ultimately,
in UIP/IPF, the inflammatory response is considered to
resemble closely the type-2 T lymphocytic pattern [16-18]
and drives the process in a profibrogenic direction.
The present study was designed to investigate by quantita-
tive immunohistochemistry the inflammatory cell pattern
in lung tissue of patients with UIP/IPF (macrophages,
neutrophils, and CD3+, CD4+, CD8+ TLs) and to correlate
their population numbers with the lung function indices
and grade of dyspnoea.
Methods
1. Subjects
The study population consisted of 12 untreated patients
with IPF and included 7 ex-smokers, and 5 never smokers
(Table 1). They were recruited from the respiratory outpa-
tient clinic of the "Evangelismos" General Hospital, Ath-
ens, Greece over a period of 3 years. The diagnosis of UIP/
IPF was based on standard criteria [19], which included
clinical findings (exertional dyspnoea, non-productive
cough, fine bibasilar inspiratory crackles), pulmonary
function tests (restrictive pattern and impaired gas
exchange), and high resolution computerized tomogra-
phy findings (bibasilar reticular abnormalities with mini-
mal ground-glass opacities consistent with the diagnosis
of IPF). The diagnosis of UIP/IPF was confirmed by video-
assisted thoracoscopic lung biopsy in all patients. Pathol-
ogy examination of these specimens clearly documented
UIP according to Katzenstein's and American Thoracic
Society – European Respiratory Society criteria (histologic
variation with alternating zones of interstitial fibrosis,
inflammation, honeycomb change, and normal lung
[1,19]. A right thoracic approach was done and two or
three samples were taken from the right lower or middle
lobe in the region of the greater fissure. Biopsy of the lin-
gular tip was avoided, as changes in this area may be par-
ticularly advanced and unrepresentative. All patients
experienced a normal and uncomplicated postoperative
course. Secondary causes of lung fibrosis were excluded:
none of the patients included in this study had a history
of environmental or occupational exposure, drug toxicity
or connective tissue disease, as documented by patient's
history and thorough clinical and immunological work
out. The study was approved by the institutional ethics
committee and informed consent was obtained from each
patient.
2. Pulmonary function tests
The pulmonary function tests included FEV1, FVC, FEV1/
FVC ratio × 100, total lung capacity (TLC), residual vol-
ume (RV) and carbon monoxide transfer factor (DLCO).
TLC and RV were measured by the helium dilution
method with a Master Screen apparatus (Erich Jaeger
GmbH, Wuerzburg, Germany), and DLCO by the single
breathholding helium dilution method [20,21]. Lung
function measurements (Table 1) were expressed as per-
centages of predicted values [20,21]. In all patients, the
arterial PaO2 and PaCO2 were also measured at rest, and
P(A-a)O2 calculated.
3. Dyspnea
Dyspnea was assessed with the modified (6-point) MRC
dyspnoea self-administered questionnaire [22] that con-
sists of six questions about perceived breathlessness: cate-
gory 0, no dyspnoea; category 1, slight degree of dyspnoea
(troubled by shortness of breath when hurrying on the
Table 1: Demographic, clinical and lung function data of all 
patients at presentation
Variables Values
Age (yr) 60 ± 2
Sex (M/F) 5/7
MRC dyspnoea score 1.8 ± 0.3
FEV1 (% pr) 85 ± 4
FVC (% pr) 78 ± 4
FEV1/FVC (ratio × 100) 85 ± 4
TLC (% pr) 64 ± 3
RV (% pr) 54 ± 4
DLCO (% pr) 50 ± 5
PaO2 (mmHg) 75 ± 2
P(A-a)O2 30 ± 3
PaCO2 (mmHg) 36 ± 3
Data are presented as means ± SEM; M = Male; F = Female; pr: 
predictedRespiratory Research 2005, 6:81 http://respiratory-research.com/content/6/1/81
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level or walking up a slight hill); category 2, moderate
degree of dyspnoea (walks slower than people of the same
age on the level because of breathlessness); category 3,
moderately severe degree of dyspnoea (has to stop
because of breathlessness when walking at own pace on
the level); category 4, severe degree of dyspnoea (stops for
breath after walking about 100 yards or after a few min-
utes on the level); category 5, very severe degree of dysp-
noea (too breathless to leave the house or breathless when
dressing or undressing).
4. Histology
Open lung biopsies from the 12 patients were used. They
were taken for diagnostic and staging purposes and were
analyzed according to the Katzenstein's criteria [1] by two
pathologists. Specimens were fixed in 4% formalin and
after dehydration embedded in paraffin. Tissue sections
were orientated and serial sections of 4 µm thickness were
cut and immunohistochemistry was performed according
to the Streptavidin-Biotin method.
5. Immunohistochemistry
To evaluate macrophages, neutrophils and the lym-
phocyte-subpopulations in lung tissues, 4 µm paraffin
sections were immunohistochemically stained with the
following mouse monoclonal antibodies (all from
DAKO, Glostrup, Denmark): macrophages-histiocytes
with anti CD68, (clone: M814, dilution 1:4000), neu-
trophils with anti-elastase (clone:M752 dilution 1:4000),
T-cells with anti-CD3 (dilution 1:200), anti-CD4 (dilution
1:100), and anti-CD8  (dilution 1:4), according to the
labeled Streptavidin-Biotin Complex method. The sec-
tions were deparaffinized and rehydrated with Tris-Buff-
ered Saline (TBS: 0.005 M Tris, 0.15 M NaCl), pH = 7.6 for
10 minutes. Endogenous peroxidase was blocked with 3%
hydrogen peroxide for 5 minutes. Then they were washed
in TBS and incubated with primary antibodies at the
appropriate dilutions for one hour. Biotinylated anti-
mouse IgG was used as a secondary antibody (DAKO),
followed by peroxidase-conjugated streptavidin (DAKO).
The peroxidase reaction was developed using 3,3'-diamin-
benzidine tetrachloride (0.25 mg dissolved in 1 ml of
0.02% hydrogen peroxide) for 3 min.
6. Lung Parenchyma Computer Image Analysis
The number of positively stained cells was determined by
observer-interactive computerized image analysis
(SAMBA microscopic image processor), whose hardware
and software have been described by Brugal and associates
[23]. This system is fitted with a standard Zeiss axioplan
microscope, a color video camera (Sony Corporation
Tokyo, Japan), an image analysis processor (matrox) and
an IBM compatible Pentium 2, 166 MHZ computer. Esti-
mation of the standard error of the mean within 95% con-
fidence limits required a maximum of at least randomly
selected 15 High Power fields (X400-Zeiss microscope)
(Analysis per area of approximately 110000 µm2). The
immunostaining was analyzed as dark brown color with
counterstained cells as false blue. Formal scoring (labeling
Index) for each antibody was then performed in one sec-
tion for each paraffin block. Interobserver variability was
very low (<0.03%). The results were expressed in percent-
age of immunopositive nuclear surface in relation to the
total nuclear surface of infiltrative cells within the tissue
(labeling Index), as previously described [24,25]. Blood
vessels, connective tissue and cartilage structures were
excluded.
7. Statistical Analysis
Data were expressed as means and standard error (SEM).
Correlation coefficients were calculated using Spearman's
rank method. A p-value of less than 0.05 was considered
statistically significant. Analysis was performed using the
SAS System software.
Results
Demographic characteristics, MRC dyspnoea score and
lung function data of all patients are listed in Table 1. All
patients claimed some degree of dyspnoea (MRC score >
0) and most patients had a restrictive lung function pat-
tern characterized by a decrease in TLC (mean value was
64% of predicted) and an increased in FEV1/FVC ratio
×100 (mean value was 85% of predicted). The DLCO was
decreased in all patients (mean value was 50% of
predicted).
Among the inflammatory cells studied T lymphocytes
(CD3+) appeared as the most numerous cells infiltrating
the lung parenchyma. They were found in aggregates,
within lymphoid follicles or diffusely within the fibrotic
lung parenchyma and mainly in the areas with moderate
or severe thickening of the alveolar wall. They were also
observed within the wall of the alveoli. The CD4+ subpop-
ulation was found in aggregates inside or around lym-
phoid follicles. A little portion of them infiltrated the lung
parenchyma diffusely, especially the alveolar wall. On the
other hand, the CD8+ cells infiltrated the parenchyma
mainly diffusely (Fig 1); they were also found within the
alveolar wall, around the fibrotic foci and in the areas with
alveolar thickening. Less commonly they were distributed
within aggregates or lymphoid follicles. Macrophages
(CD68+ cells) were preferentially located in the lamina
propria of the airways compared with the surface epithe-
lium and the submucosa. They were also distributed in
large aggregates in the dilated alveolar spaces. Neutrophils
(Elastase+) were mainly observed in the surface epithe-
lium and within the alveolar wall.
Elastase positive cells accounted for the 7.04% ± 1.1 of
total cells, CD68+ cells for the 16.6% ± 2, CD3+ TLs for theRespiratory Research 2005, 6:81 http://respiratory-research.com/content/6/1/81
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28.8% ± 7, CD4+ TLs for the 14.5 ± 4 and CD8+ TLs for the
13.8 ± 4. Among the infiltrating inflammatory cells,
CD8+TLs were inversely correlated with FVC % predicted
(rs = -0.67, p = 0.01) (Fig 2), TLC % predicted (rs = -0.68,
p = 0.01) (Fig 3), DLCO % predicted (rs = -0.61, p = 0.04),
PaO2 (rs = -0.60, p = 0.04). Positive and statistically signif-
icant correlations were found between CD8+TLs and P(A-
a)O2 (rs = 0.65, p = 0.02) and CD8+TLs and MRC score (rs
= 0.63, p = 0.02) (Fig 4). Additionally, the CD68+ cells pre-
sented significant negative correlations with the FVC %
predicted (rs = -0.80, p = 0.002) and the FEV1 % predicted
(rs = -0.68, p = 0.01). Elastase positive cells, CD3+ TLs, and
the CD4+ TLs did not correlate with any of the functional
indices as well as the MRC score.
Discussion
Several studies have implicated a role of inflammation in
the pathogenesis of lung damage in IPF. Parenchymal
lung damage leads to defects in mechanics and gas
exchange and consequently to exertional dyspnoea, the
The CD8+TLs infiltrate diffusely the lung parenchyma (scale bar = 25 µm) Figure 1
The CD8+TLs infiltrate diffusely the lung parenchyma (scale bar = 25 µm).
Relationship between CD8+TLs (% of total cells) and TLC (%  predicted), (rs = -0.68, p = 0.01) Figure 3
Relationship between CD8+TLs (% of total cells) and TLC (% 
predicted), (rs = -0.68, p = 0.01).Respiratory Research 2005, 6:81 http://respiratory-research.com/content/6/1/81
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most prominent and disabling symptom in these patients.
This study shows that the type of the inflammatory infil-
trate in lung tissue of patients with UIP/IPF was
predominantly mononuclear, and that among the differ-
ent inflammatory cells, CD8+ TLs correlated significantly
with both functional [FVC, TLC, DLCO, PaO2, P(A-a)O2]
and clinical indices (the MRC chronic dyspnoea score) of
the disease severity and extent studied and macrophages
(CD68+ cells) with some of the functional indices studied
(FVC and FEV1).
Previous studies have shown that a patchy chronic inter-
stitial inflammatory process coexists with an abnormal
extracellular matrix deposition, foci of fibroblasts, and
alveolar collapse in lung tissue of subjects with IPF
[1,2,8,26]. This inflammatory component in tissue speci-
mens appeared to consist primarily of mononuclear cells
(macrophages, lymphocytes and plasma cells) while the
presence of the other inflammatory cells such as neu-
trophils and eosinophils appeared less numerous
[5,8,26,27]. Previous studies of immunohistochemical
analysis including the TLs subpopulations of lung tissue
in IPF [5,8,28,29] and other interstitial pneumonias [30]
have shown that the inflammatory process is mainly
mononuclear, and that both CD4+ and CD8+ TLs were well
represented and diffusely distributed in the interstitium,
with an additional component of the CD4+ TLs observed
inside lymphoid follicles. Our findings do not contrast
these observations.
Few studies have attempted to evaluate the structure-func-
tion relationship in IPF, and their findings are not always
in agreement [31-35]. The selection of patients and the
different methodologies might, at least in part, explain
discrepancies. Our findings come into agreement with the
studies by Fulmer and coworkers [31] and Chinet and
coworkers [35] who found significant correlations
between the degree of inflammation and lung volumes
and some index of gas exchange. Gaensler and Carrington
[34] also reported correlations between physiological
indices and an estimate of functional impairment from
histology (designated by them as pathological severity) in
a large but mixed population (502 patients) with "inter-
stitial lung disorders" including 64 patients with UIP.
However, comparisons with previous studies are not
always possible for the following reasons. First, we used a
different methodology than the above-cited works. This is
the first study attempted to correlate cell counts including
TLs subpopulations in tissue biopsies with clinical and
physiological parameters. This should be in relation to the
fact that reliable cell counts were not feasible with the past
technologies. Second, older studies might have included a
mixed population of patients with UIP/IPF, patients with
non-specific interstitial pneumonia and patients with
pulmonary fibrosis associated with collagen vascular dis-
orders since there were not defined strict criteria for these
entities, by that time [36]. Finally, the patients' selection
and the effect of previous treatment might have influ-
enced the results.
Inflammatory cells including subpopulations of TLs have
been also studied in IPF by bronchoalveolar lavage (BAL)
[4] and many of the conclusions regarding the role of
inflammation in interstitial lung disorders have been
drawn from these studies. The possible role of lym-
phocytes in the pathogenesis of IPF traditionally received
little investigation since increase in their number is an
uncommon finding in BAL samples. Hence, early BAL
studies have driven attention into neutrophils as well as
macrophages. However, evidence from animal models
Relationship between CD8+TLs (% of total cells) and FVC (%  predicted), (rs = -0.67, p = 0.01) Figure 2
Relationship between CD8+TLs (% of total cells) and FVC (% 
predicted), (rs = -0.67, p = 0.01).
Relationship between CD8+TLs (% of total cells) and MRC  dyspnea score, (rs = 0.63, p = 0.02) Figure 4
Relationship between CD8+TLs (% of total cells) and MRC 
dyspnea score, (rs = 0.63, p = 0.02).Respiratory Research 2005, 6:81 http://respiratory-research.com/content/6/1/81
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appears to suggest that lymphocytes do play a role in
fibrosis [4]. Furthermore, studies on BAL lymphocytes
have shown that CD8+ TLs are prominent in BAL in IPF
[36] and may also be associated with a worse prognosis
[37]. T lymphocytes and their phenotypic and functional
characteristics have been more extensively studied in scle-
roderma fibrosis [38-43]. IPF and scleroderma fibrosis are
two fibroses with different prognoses [41]. This might be
related to the fact that most patients with scleroderma
develop a less aggressive form of fibrosing interstitial
pneumonia, the non-specific interstitial pneumonia
(NSIP) [42]. Indeed, studies that compared the prognosis
of patients with "idiopathic" NSIP to that of patients with
usual interstitial pneumonia type/IPF have clearly shown
that the former present a far better prognosis than the lat-
ter [43]. Recent studies with BAL in scleroderma patients
have shown that a subset of them, who present more than
15% lymphocytes in BAL [38], or have activated, long-
lived CD8+ T cells [40], or produce type 2 cytokines (IL-4
and IL-5) by the CD8+ TLs [39], present a more aggressive
form of interstitial pneumonia. Hence, TLs and in partic-
ular the CD8+ subset may be associated with progressive
fibrosis in scleroderma resembling more patients with
IPF.
Notwithstanding correlations do not imply direct cause-
effect relationships, we think that the significant negative
correlations observed in this group of patients with IPF
between CD8+TLs and functional indices and the positive
correlation observed between the same cells and clinical
indices estimating the disease severity as well as the corre-
lation between CD68+ cells with FVC and FEV1 might sug-
gest a potential pathophysiologic relevance for
mononuclear cells and especially CD8+TLs in the patho-
genesis of pulmonary fibrosis. However, the mechanisms
related to these correlations and the relationship of
inflammatory and immune parameters to structural
changes in the lung parenchyma still remain unknown
and further studies are needed for their clarification.
The increase in CD8+ TLs observed in lung surgical biop-
sies in patients with IPF appears intriguing. Classically,
the major role of CD8+ TLs in the inflammatory response
has been considered the rapid resolution of viral infec-
tions [44]. It has also become evident that CD8+ TLs may
contribute to lung injury [45,46]. Viruses have been impli-
cated in the pathogenesis of IPF, and a higher incidence of
viral infections (Ebstein Barr Virus, influenza, cytomega-
lovirus, and possibly Hepatitis C virus) has been reported
in these patients [19]. Recently, it has been hypothesized
that in patients with IPF an excessive recruitment of CD8+
TLs may occur in response to recurrent or persistent viral
infections, and this excessive response may play a role for
the development of lung damage [47]. The above hypoth-
esis has received some experimental confirmation by the
studies of Enelow and coworkers [47] and Small and cow-
orkers [48] who have shown that antigen-specific CD8+ T
cell recognition of an alveolar epithelial "autoantigen" is
sufficient to trigger an inflammatory cascade that results
in the histological and physiological manifestations of
interstitial pneumonia. CD8+ TLs can differentiate into
cells that make IFN-γ but no IL-4 (Tc1 cells) promoting
attenuation of fibrosis and cells that make IL-4 but not
IFN-γ (Tc2 cells) leading to exuberant fibrosis [49].
Though further studies are necessary to address the spe-
cific role of the Tc2 cells in pulmonary fibrosis, some data
such as the upregulation of genes encoding immunoglob-
ulins and extracellular matrix proteins in IPF lung tissue
[50] appear to suggest that the predominance of type-2
immune response in IPF [51] is what drives the process in
profibrogenic direction.
Conclusion
We found that the type of the inflammatory cell infiltrate
in surgical biopsies of patients with UIP/IPF was predom-
inantly mononuclear. Among the different inflammatory
cells revealed by immunohistochemistry, the CD8+TLs
correlated significantly with both functional [FVC, TLC,
DLCO, PaO2, P(A-a)O2] and clinical indices (the MRC
chronic dyspnoea score) of disease severity and extent
studied and the CD68+ cells with FVC and FEV1. These data
might suggest a potential role for mononuclear cells and
especially CD8+TLs in the pathogenesis of pulmonary
fibrosis. However, because of the relatively small size of
the population studied, further studies are needed to sup-
port our findings.
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